MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 10/03/22
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development DayBusiness Wire • 10/03/22
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks RedomicileBusiness Wire • 09/26/22
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR RedomicileBusiness Wire • 09/16/22
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual CongressBusiness Wire • 09/12/22
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to DelawareBusiness Wire • 09/08/22
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid CancersBusiness Wire • 09/04/22
Zymeworks Inc. (ZYME) CEO Ken Galbraith on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsBusiness Wire • 08/04/22
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in ParisBusiness Wire • 07/25/22
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of CompanyBusiness Wire • 06/10/22
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meetingMarket Watch • 05/27/22
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022Business Wire • 05/26/22
Zymeworks rejects 'unsolicited, opportunistic' buyout bid by UAE-based All Blue FalconsMarket Watch • 05/20/22
Zymeworks' Board of Directors Unanimously Rejects Unsolicited, Non-Binding ProposalBusiness Wire • 05/20/22
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.PRNewsWire • 05/19/22
Zymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22